Recent clinical research has found that lower levels of circulating IL-17 are significantly associated with a higher risk of major cardiovascular events, including all-cause death and recurrent myocardial infarction (MI), after adjustment for other known prognostic factors, including C-reactive protein and statin treatment [42]. Here, IL17A is linked to myocardial infarction.